Clinical Trials Browser

Phase 4 × trastuzumab biosimilar HLX02 × 30 days × Clear all

NCT05376878 2026-02-23

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Phase 4 Recruiting

Brain Neoplasms, Breast Neoplasms